1-Methyl-[1,4]diazocane | 57591-16-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Methyl-[1,4]diazocane
• 英文别名: 1-Methyl-1,4-diazocane
• CAS: 57591-16-9
• 化学式: C₇H₁₆N₂
• mdl: MFCD19221309
• 分子量: 128.217
• InChiKey: PAAPABZWHJCWPH-UHFFFAOYSA-N

物化性质

• 沸点：
  182.6±8.0 °C(Predicted)
• 密度：
  0.860±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Methyl-[1,4]diazocane 以31%的产率得到
  参考文献：
  名称：

  HERNANDEZ-MORA J.; CORDERO-ANTUNANO N., CARIB. J. SCI. , 1975, 14, NO 3-4, 77-82

  摘要：

  DOI：
• 作为产物：
  描述：

  1,4-Diazocane-1-carbaldehyde 以93%的产率得到
  参考文献：
  名称：

  HERNANDEZ-MORA J.; CORDERO-ANTUNANO N., CARIB. J. SCI. , 1975, 14, NO 3-4, 77-82

  摘要：

  DOI：

文献信息

• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160159773A1

  公开（公告）日：2016-06-09

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的，或其盐。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150031661A1

  公开（公告）日：2015-01-29

  The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

  本发明涉及一种吡嗪化合物，可用作ATR蛋白激酶的抑制剂。本发明还涉及包含本发明化合物的药学上可接受的组合物；使用本发明化合物治疗各种疾病、疾病和病况的方法；制备本发明化合物的过程；制备本发明化合物的中间体；以及在体外应用中使用化合物的方法，如研究生物和病理现象中的激酶，介导这些激酶的细胞内信号转导途径的研究，以及新激酶抑制剂的比较评估。本发明化合物具有以下式I：其中变量如本文所定义。
• BICYCLIC PYRROLE DERIVATIVES
  申请人：Nakahira Hiroyuki

  公开号：US20090192129A1

  公开（公告）日：2009-07-30

  Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) wherein the solid line and dotted line between A 1 and A 2 represents a double bond (A 1 =A 2 ) or the like; A 1 is C(R 4 ) or the like; A 2 is nitrogen atom or the like; R 1 is hydrogen atom, optionally substituted alkly group, or the like; R 2 is hydrogen atom, optionally substituted alkyl group, or the like; R 3 is hydrogen atom, halogen atom, or the like; R 4 is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A) [wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R 6 or substituted with one or two R 6 's which are each independently halogen atom or the like.]

  提供了由通式（I）表示的化合物，其前药或两者的药物可接受的盐，这些化合物具有高DPP-IV抑制活性，并在安全性，毒性等方面得到改善：（I），其中A1和A2之间的实线和虚线表示双键（A1 = A2）或类似物; A1是C（R4）或类似物; A2是氮原子或类似物; R1是氢原子，可选地取代的烷基或类似物; R2是氢原子，可选地取代的烷基或类似物; R3是氢原子，卤原子或类似物; R4是氢原子，羟基，卤原子或类似物; Y是由通式（A）或类似物表示的基团;（A）[其中m1为0,1,2或3;基团（A）可以从R6中释放或用一个或两个R6（它们各自独立地是卤原子或类似物）取代]。
• COMPOUNDS
  申请人：Baeschlin Daniel Kaspar

  公开号：US20090192138A1

  公开（公告）日：2009-07-30

  The invention provides novel deazaxanthine and deazahypoxanthine compounds. The compounds may be useful in the therapy of diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated.

  本发明提供了新型的脱氮黄质和脱氮次黄嘌呤化合物。这些化合物可用于治疗与二肽基肽酶-IV（DPP-IV）有关的疾病和病况。
• NOVEL COMPOUNDS, THEIR PREPARATION AND USE
  申请人：NEUROSEARCH A/S

  公开号：EP1406900A1

  公开（公告）日：2004-04-14